TABLE 3

Other Secondary Outcomes

OutcomeControl Group (n = 143)SLI Group (n = 148)P
Highest Fio2, %35 (30–50)40 (25–45).57
Surfactant doses, h1 (1–2)1 (1–2).55
nCPAP duration, h190 (47–500)218 (42–480).88
BiPAP duration, h138 (48–336)132 (50–432).62
Nasal IMV duration, h96 (23–234)108 (24–320).63
SIMV/SIPPV/PSV duration, h118 (24–216)96 (24–288).81
HFV duration, h72 (16–150)94 (33–177).58
Duration of in-hospital stay, da75 (60–101)83 (61–107).22
  • Data are presented as median (interquartile range). BiPAP, bilevel positive airway pressure; HFV, high-frequency ventilation; PSV, pressure support ventilation; SIMV, synchronized intermittent MV; SIPPV, synchronized intermittent positive pressure ventilation.

  • a Proportions are estimates of cumulative incidence of events in presence of competing risks.